We found that the tumor growth was inhibited by both conventional TCR-T and IL-21R-TCR-T treatment and was persistently inhibited in mice receiving IL-21R-TCR-T (Fig. 5h), demonstrating the robust long-lasting in vivo antitumor efficacy of IL-21R-TCR-T. This evidence concerns the gene IL21R and neoplasm.